                         SEQUENCE LISTING

<110>  Flagship Pioneering Innovations VI, LLC
 
<120>  METHODS OF ENRICHING FOR CIRCULAR POLYRIBONUCLEOTIDES

<130>  51509-034WO2

<150>  US 63/190,060
<151>  2021-05-18

<160>  27    

<170>  PatentIn version 3.5

<210>  1
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  1

Cys Ala Ala Thr Cys Gly Ala Cys Gly Gly Thr Cys Cys Cys Cys Cys 
1               5                   10                  15      


Thr Ala Gly Ala Ala Gly Ala Thr Ala Thr Gly Cys Thr Gly 
            20                  25                  30  


<210>  2
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Val or Ile

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is any amino acid

<400>  2

Asp Xaa Glu Xaa Asn Pro Gly Pro 
1               5               


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  3

Gly Asp Val Glu Ser Asn Pro Gly Pro 
1               5                   


<210>  4
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  4

Gly Asp Ile Glu Glu Asn Pro Gly Pro 
1               5                   


<210>  5
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  5

Val Glu Pro Asn Pro Gly Pro 
1               5           


<210>  6
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  6

Ile Glu Thr Asn Pro Gly Pro 
1               5           


<210>  7
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  7

Gly Asp Ile Glu Ser Asn Pro Gly Pro 
1               5                   


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  8

Gly Asp Val Glu Leu Asn Pro Gly Pro 
1               5                   


<210>  9
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  9

Gly Asp Ile Glu Thr Asn Pro Gly Pro 
1               5                   


<210>  10
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  10

Gly Asp Val Glu Asn Pro Gly Pro 
1               5               


<210>  11
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  11

Gly Asp Val Glu Glu Asn Pro Gly Pro 
1               5                   


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  12

Gly Asp Val Glu Gln Asn Pro Gly Pro 
1               5                   


<210>  13
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  13

Ile Glu Ser Asn Pro Gly Pro 
1               5           


<210>  14
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  14

Gly Asp Ile Glu Leu Asn Pro Gly Pro 
1               5                   


<210>  15
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  15

His Asp Ile Glu Thr Asn Pro Gly Pro 
1               5                   


<210>  16
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  16

His Asp Val Glu Thr Asn Pro Gly Pro 
1               5                   


<210>  17
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  17

His Asp Val Glu Met Asn Pro Gly Pro 
1               5                   


<210>  18
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  18

Gly Asp Met Glu Ser Asn Pro Gly Pro 
1               5                   


<210>  19
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  19

Gly Asp Val Glu Thr Asn Pro Gly Pro 
1               5                   


<210>  20
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  20

Gly Asp Ile Glu Gln Asn Pro Gly Pro 
1               5                   


<210>  21
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  21

Asp Ser Glu Phe Asn Pro Gly Pro 
1               5               


<210>  22
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is absent or Gly or His

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is absent or Asp or Gly

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is Asp or Val or Ile or Ser or Met

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is any amino acid

<400>  22

Xaa Xaa Xaa Glu Xaa Asn Pro Gly Pro 
1               5                   


<210>  23
<211>  9
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  r is a or g

<400>  23
ccrccaugg                                                                9


<210>  24
<211>  96
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  24
ggcucaucuc gacaagaggc ggcaguccuc aguacucuua cucuuuucug uaaagaggag       60

acugcuggac ucgccgccca aguucgagca ugagcc                                 96


<210>  25
<211>  74
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  25
ggcuagaggc ggcaguccuc aguacucuua cucuuuucug uaaagaggag acugcuggac       60

ucgccgcccg agcc                                                         74


<210>  26
<211>  90
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  26
cgggucggca uggcaucucc accuccucgc gguccgaccu gggcauccga aggaggacgc       60

acguccacuc ggauggcuaa gggagagcca                                        90


<210>  27
<211>  88
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  27
uggccggcau ggucccagcc uccucgcugg cgccggcugg gcaacauucc gaggggaccg       60

uccccucggu aauggcgaau gggaccca                                          88


